U.S. Senate committee holds hearing with Novo Nordisk’s CEO
After a while, Tuesday’s U.S. Senate committee hearing with Novo Nordisk’s CEO became less a roasting of Novo’s pricing of Wegovy and Ozempic and more a roasting of pharmacy benefit managers for merely existing. Members of the Senate Health, Education, Labor & Pensions didn’t really follow the lead of the panel’s chairman, Vermont independent Sen. […]